An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Advanced Solid Tumors

In brief

This study is designed to evaluate the response of several biomarkers in patients treated with ARQ 501. The results of the study may help the sponsor understand the effect of the study drug on these biomarkers and their respective role in cancer growth control.

Key facts

Study ID

NCT00524524

Run by

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

People needed

9

Starts

2007-08-01

Expected to finish

2008-08-01

Last updated by the study team

2011-10-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Able to provide signed and dated informed consent prior to study-specific screening procedures.
• Patients must have histologically or cytologically confirmed advanced solid tumor(s).
• Measurable disease as defined by RECIST (see Section 9.0).
• Patients must have Karnofsky performance status (KPS) ≥ 70%.
• Male or female patients of child-producing potential must agree to contraception or avoidance of pregnancy measures during the study and for 30 days after the infusion of ARQ 501.
• Females of childbearing potential must have a negative serum pregnancy test within seven days prior to the administration of study drug.
• ≥ 18 years old.
• Hemoglobin ≥ 10 g/dL
• Absolute neutrophil count (ANC) ≥ 1.5 x 10 9/L (≥1,500/mm3).
• Platelets ≥ 100 x 10 9/L (≥ 100,000/mm3).
• Total bilirubin ≤ 1.5 x upper limit of normal (ULN) or ≤ 3.0 x ULN with metastatic liver disease.
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN or ≤ 5.0 x ULN with metastatic liver disease.
• Creatinine ≤ 1.5 × ULN

You may not qualify if…

• Active, uncontrolled systemic infection considered opportunistic, life threatening or clinically significant at the time of treatment
• Received anticancer chemotherapy, immunotherapy, radiotherapy, surgery or investigational agents within four weeks of first infusion
• Symptomatic or untreated central nervous system (CNS) involvement
• Previous exposure to ARQ 501

Where it is running

• Dana Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.